Sun Pharmaceutical planning to acquire Israel-based Taro Pharmaceutical Industries

29 May 2023 Evaluate

Sun Pharmaceutical Industries is planning to fully acquire Israel-based Taro Pharmaceutical Industries through a reverse triangular merger. It has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of $38 per ordinary share in cash. Sun Pharma currently owns a 78.48 per cent stake in Taro.

The purchase price represents a premium of 31.2 per cent over Taro's closing price on May 25, 2023, a 41.5 per cent premium over Taro's average closing price in the last 60 days and a compelling liquidity opportunity for Taro's shareholders. Under the indicative proposal, post the acquisition, Taro will become a wholly-owned subsidiary of Sun Pharma and will be delisted from NYSE. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1612.00 -61.55 (-3.68%)
20-Jan-2026 15:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1381.00
Zydus Lifesciences 872.95
Lupin 2160.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×